KDL Biotech Ltd (KOPDRUGS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532291 | NSE: KOPDRUGS | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

KDL Biotech Ltd (KOPDRUGS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532291 | NSE: KOPDRUGS | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on KDL Biotech

Based on:

M-Cap below 100cr DeciZen not available

KDL Biotech stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
5.1 Cr.
52-wk low:
2.1
52-wk high:
2.1

Is an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of KDL Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'02Mar'03Mar'04Sep'05Mar'06Sep'07Sep'08Mar'10Mar'11Mar'12TTM
ROCE % 9.7%6.1%2.8%-21.7%-5.4%-0.6%-11.5%-15.3%-101.9%-108.4%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 20419312410611011356.825.628.426.50
Sales YoY Gr.--5.2%-35.9%-14.7%4.4%2.3%-49.7%-55%11%-6.8%-
Adj EPS 2.11.4-1.8-17.2-13.5-5.4-8.5-6-23.4-7.2-5.9
YoY Gr.--31.7%-228.6%NANANANANANANA-
BVPS (₹) 35.536.135.26.90.3-0.116.46.2-17.5-24.6-42.5
Adj Net
Profit
3.42.4-3-28.9-22.6-9-20.4-14.5-56.3-17.2-14
Cash Flow from Ops. -10.634.914.26.4-1.91.7-6.32.21.66.8-
Debt/CF from Ops. -7.2257.9-84.332.2-10.217.738.48.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -20.3%-24.9%-22.5%-6.8%
Adj EPS -214.9%NANANA
BVPS-196%-343.1%-214.6%NA
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'02Mar'03Mar'04Sep'05Mar'06Sep'07Sep'08Mar'10Mar'11Mar'12TTM
Return on
Equity %
4.12.6-3.3-64.7-31.5-104-104.5-70.2573.93417.6
Op. Profit
Mgn %
9.88.210.1-11.7-6.2-6.4-14.9-26.4-57.6-7.8NAN
Net Profit
Mgn %
1.71.2-2.4-27.3-20.4-8-35.9-56.5-198.1-65-INF
Debt to
Equity
0.90.80.81.83-308.81.62.6-1.4-1-
Working Cap
Days
1471421821273281292982111661070
Cash Conv.
Cycle
626358399022-37-60-56-180

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - KDL Biotech Ltd.

Standalone Consolidated
TTM EPS (₹) -5.9 -
TTM Sales (₹ Cr.) 0 -
BVPS (₹.) -42.5 -
Reserves (₹ Cr.) -126 -
P/BV -0.05 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 2.14 / 2.14
All Time Low / High (₹) 1.61 / 413.35
Market Cap (₹ Cr.) 5.1
Equity (₹ Cr.) 24
Face Value (₹) 10
Industry PE 40.6

Management X-Ray of KDL Biotech:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of KDL Biotech - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of KDL Biotech

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'02Mar'03Mar'04Sep'05Mar'06Sep'07Sep'08Mar'10Mar'11Mar'12
Sales203.98193.48124.03158.7055.24169.5456.8438.3828.4126.47
Operating Expenses 184.03177.53111.50177.1958.65180.3466.3248.5044.7628.53
Manufacturing Costs6.336.126.8910.517.4413.7411.7112.5911.8212.07
Material Costs164.38156.5990.63127.6244.22150.0833.9216.837.644.63
Employee Cost 6.266.126.5810.603.5711.327.7914.079.369.65
Other Costs 7.078.717.3928.473.425.1912.905.0115.952.18
Operating Profit 19.9415.9412.53-18.49-3.41-10.80-9.47-10.12-16.36-2.07
Operating Profit Margin (%) 9.8%8.2%10.1%-11.7%-6.2%-6.4%-16.7%-26.4%-57.6%-7.8%
Other Income 0.550.320.341.420.9420.465.631.860.320.76
Interest 8.499.398.4913.385.1412.9410.352.996.746.77
Depreciation 6.086.538.4812.833.6310.206.9012.4022.359.13
Exceptional Items 00000006.66-11.500
Profit Before Tax 5.920.34-4.10-43.28-11.25-13.48-21.09-16.99-56.62-17.21
Tax 2.18-2.02-1.100.020.030.060.040.027.690
Profit After Tax 3.752.36-3-43.30-11.28-13.55-21.13-17.01-64.31-17.21
PAT Margin (%) 1.8%1.2%-2.4%-27.3%-20.4%-8.0%-37.2%-44.3%-226.0%-65.0%
Adjusted EPS (₹)2.21.4-1.8-25.8-6.7-8.1-8.8-7.1-26.8-7.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'02Mar'03Mar'04Sep'05Mar'06Sep'07Sep'08Mar'10Mar'11Mar'12

Equity and Liabilities

Shareholders Fund 89.2291.5888.5845.2926.31-0.2739.3622.35-41.96-59.17
Share Capital 42.8342.8342.8342.8342.8316.7624.0424.0424.0424.04
Reserves 46.3948.7545.752.46-16.52-17.0315.33-1.68-66-83.21
Minority Interest0000000000
Debt75.9568.8771.1376.0679.9782.8664.2557.3751.3051.42
Long Term Debt75.9568.8771.1376.0679.9782.8664.2557.370.010.04
Short Term Debt0000000051.2951.38
Trade Payables30.4231.7826.1626.5828.3852.9210.8721.785.335.48
Others Liabilities -0.330.99-3.66-1.054.9110.45-2.92-3.1950.6858.97
Total Liabilities 195.25193.22182.22146.88139.57145.96111.5798.3165.3556.70

Fixed Assets

Gross Block124.80149.56150.59151.41138.73140.35144.48154.79154.97155.16
Accumulated Depreciation24.2330.7339.2151.8852.1362.3067.6380.0391.36100.45
Net Fixed Assets 100.57118.83111.3799.5386.6078.0576.8574.7663.6154.71
CWIP 0000005.984.4000
Investments 0.010.020.020.020.020.020.020.020.010.01
Inventories43.0520.9617.1117.2414.2929.675.203.472.702.51
Trade Receivables31.9932.8330.9223.9331.8622.581.040.070.290.02
Cash Equivalents 1.682.152.552.900.880.301.340.720.480.54
Others Assets 17.9518.4420.263.255.9315.3521.1414.89-1.74-1.08
Total Assets 195.25193.22182.22146.88139.57145.96111.5798.3165.3556.70

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'02Mar'03Mar'04Sep'05Mar'06Sep'07Sep'08Mar'10Mar'11Mar'12
Cash Flow From Operating Activity -10.6034.9014.199.60-0.952.57-6.313.251.576.79
PBT 5.920.34-4.10-43.28-11.25-13.48-21.09-16.99-64.31-17.21
Adjustment 15.6617.5018.9346.0313.521.4124.8910.4062.1015.65
Changes in Working Capital -23.6826.64-0.626.89-2.7914.72-10.079.854.218.78
Tax Paid -0.01-0.19-0.02-0.05-0.43-0.08-0.04-0.02-0.43-0.43
Cash Flow From Investing Activity -2.92-27.35-0.93-0.79-0.29-1.55-15.03-0.66-0.08-0
Capex -1.13-24.76-1.03-1-0.35-1.59-15.09-0.82-0.15-0.24
Net Investments -0.01-000000000
Others -1.78-2.590.100.210.060.040.060.160.060.24
Cash Flow From Financing Activity 14.47-7.08-12.86-8.45-0.78-1.6022.38-3.21-1.79-6.73
Net Proceeds from Shares 0000008.73000
Net Proceeds from Borrowing 14.47-7.08001.52-41.130000.03
Interest Paid 00-4.60-7.060-4.50-10.27-2.99-1.84-6.77
Dividend Paid 0000000000
Others 00-8.26-1.40-2.3044.0323.92-0.220.050
Net Cash Flow 0.940.470.400.36-2.02-0.581.03-0.62-0.300.06

Finance Ratio

PARTICULARSMar'02Mar'03Mar'04Sep'05Mar'06Sep'07Sep'08Mar'10Mar'11Mar'12
Ratios
ROE (%)6.833.94-5.02-113.41-127.67N/A-108.11-55.12N/AN/A
ROCE (%)9.656.142.81-21.69-5.41N/A-11.54-15.27N/AN/A
Asset Turnover Ratio1.11.040.71.020.421.260.470.380.350.45
PAT to CFO Conversion(x)-2.8314.79N/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days565988591695572522
Inventory Days745853379645106403935
Payable Days77591047422799343354648426

KDL Biotech Ltd Stock News

KDL Biotech Ltd FAQs

The current trading price of KDL Biotech on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of KDL Biotech stood at ₹5.14.
The latest P/E ratio of KDL Biotech as of 31-Dec-1969 is 0.00.
The latest P/B ratio of KDL Biotech as of 31-Dec-1969 is -0.05.
The 52-week high of KDL Biotech is ₹2.14 and the 52-week low is ₹2.14.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of KDL Biotech is ₹0.00 ( Cr.) .

About KDL Biotech Ltd

KDL Biotech, formerly known as Kopran Drugs was incorporated on August 12, 1986 as a private limited company. The bulk drugs division of Kopran at Khopoli was demerged and merged into KDL Biotech with effect from January 1, 1998 pursuant to order u/s 391 to 394 of the Companies Act by the Bombay High Court. The company is a joint venture between Kopran of Parijat Enterprises, India and Synpac Kingdom Pharmaceuticals of Koo Group, Taiwan.

KDL has a biotechnology division, which manufactures Penicillin-G acylase, the enzyme used for conversion of penicillin to 6APA. It has also successfully developed Bleomycin, an anti-cancer drug and a cytoxic antibiotic. The products under development include mitomycin, another anti-cancer drug and Vancomycin, an anti- bacterial.

KDL is one of the largest manufacturers of semi synthetic penicillin in Asia. From a 12 tonne per annum capacity in 1982-83, it expanded to a present capacity of 1200 tonnes per annum. The company's plant is approved by UK MCA, US FDA, South African MCC and several countries with strict compliance of GMP and GLP.

Milestones:

2000 - The union had declared a strike at the company's factory situated at Village Savroli, Taluka Khalapur, Khopoli, District Raigad, Maharashtra. The company's major foray into the business of biotechnology based products it was proposed to change the name of the company from Kopran Drugs to KDL Biotech for which necessary approval was been received from Registrar of Companies, Maharashtra, Mumbai. The company is a major producer of semi-synthetic penicillins (SSP) and the enzyme for converting penicillin-G to 6APA.    

2001- Crisil downgraded the company's NCDs issue to `BB+' from `BBB'.

Products:

1. Finished Dosage Forms

• Antibiotics/Antibacterial s• Anti-Malarial • Cadiovasculars • Pain Management • Anthelminthics

2. Active Pharmaceutical Ingredients

• Anti-hypertensives • Macrolides • Taste Masked • Cephalosporins

Subsidiary:

• Kopran Research Laboratories

Group companies:

• Oriental Containers • United Shippers • Shinrai Toyota • Claridge Moulded Fibre • Kopran

Alliances:

• Gujarat Themis Biosyn • Kampala Pharmaceutical Industries, Uganda

Strategic Business Units:

• Finished Dosage Forms

• Active Pharmaceutical Ingredients

• Research & Development

• Kopran Laboratories

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×